Hogan Lovells advises Jennewein shareholders on its dual-track exit

Hogan Lovells advises Jennewein shareholders on its dual-track exit

Press releases | 29 September 2020

Led by partners Peter Huber and Michael Schlitt, international law firm Hogan Lovells has advised the shareholders of Jennewein Biotechnologie GmbH on its EUR 310 million merger with Danish biotechnology company Chr. Hansen.

Jennewein Biotechnologie announced its plan to IPO in January 2020. However, following strong interest by shareholders for a complete sale, it was agreed that they would run a structured bidding process, parallel to the IPO plans. The negotiations on the M&A track progressed rapidly, with shareholders finally agreeing on a sale to Chr. Hansen on September 22, 2020. 

Jennewein Biotechologie, an international leader in the field of industrial biotechnology, was the world’s first company to commercially produce HMOs, complex carbohydrate structures found in breast milk, to key markets. Over the past 15 years, Jennewein Biotechnologie has built up an IP portfolio with more than 200 approved patents and a global client base. 

The Hogan Lovells team advice Jennewein Biotechnologie and its shareholders with two teams on the IPO and the sale to Chr. Hansen.

Hogan Lovells team for Jennewein Biotechnologie GmbH and the shareholders

Peter Huber (lead Partner Corporate/M&A, Munich);

Prof. Dr. Michael Schlitt (lead Partner IPO, Capital Markets, Frankfurt);

Andreas Thun (Counsel), Dr. Tobias Kahnert (Counsel), Dr. Peter Lang (Senior Associate), Kilian Pfahl, Elisabeth Rothenaicher, Christopher Hildebrandt (Associates), Christian Alscher (Business Lawyer) (all Corporate/M&A, Munich);

Dr. Susanne Ries (Of Counsel), Mark Devlin (Counsel), Daria Latysheva (U.S Securities Senior Associate), Timo Lockemann, Christian Schröder (Associates), Eva-Christina Sommer (Business Lawyer) (all Capital Markets, Frankfurt);

Dr. Marcus Schreibauer (Partner), Dr. Marion Fischer (Counsel), Sarah-Lena Kreutzmann (Counsel) (all Intellectual Property, Dusseldorf/ Munich);

Dr. Alexander Klicznik (Partner), Dr. Felipe Zilly (Counsel), Caroline Bley (Senior Associate/ Patent Attorney) (all Patents, Dusseldorf);

Dr. Heiko Gemmel (Partner), Dr. Falk Loose (Counsel), Anne-Svenja de Kiff (Senior Associate) (all Tax, Dusseldorf/ Munich);

Dr. Christoph Wünschmann (Partner, Antitrust, Munich);

Dr. Falk Schöning (Partner, Foreign Investment, Brussels);

Dr. Heiko Tschauner (Partner, Finance, Munich);

Dr. Sabrina Gäbeler (Counsel), Rebecca Reinhardt (Associate) (both Employment, Frankfurt).